Education
About Us
Working with TipRanks
Follow Us
Pulmatrix (PULM)
NASDAQ:PULM
PULM Stock Chart & Stats
$4.81
-$0.25(-3.99%)
At close: 4:00 PM EST
$4.81
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.96 - $10.40
Previous CloseN/A
Volume31.27K
Average Volume (3M)16.44K
Market Cap
$16.95M
Enterprise Value$12.96M
Total Cash (Recent Filing)$5.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding3,652,285
10 Day Avg. Volume25,700
30 Day Avg. Volume16,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue35.11
Enterprise Value/Gross Profit35.11
Enterprise Value/Ebitda-1.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.96 and its highest was $10.40 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $16.95M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Mar 26, 2026 which is in 158 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on Oct 16, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.24.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.521%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
Pulmatrix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
137.04%
12-Months-Change
Fundamentals
Return on Equity
-79.47%
Trailing 12-Months
Asset Growth
-56.72%
Trailing 12-Months
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biopharmaceutical company that specializes in developing inhaled therapies to address serious pulmonary diseases. Operating in the biotechnology and healthcare sectors, the company focuses on leveraging its proprietary iSPERSE™ technology, a dry powder delivery platform, to create novel inhaled treatments. Pulmatrix's core products aim to treat a range of respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
Technical Analysis
Ownership Overview
―
Insiders
2.24% Mutual Funds
<0.01% Other Institutional Investors
96.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---